Pharmamarketeer

Samsung Bioepis oncology biosimilar Ontruzant receives US FDA approval

Samsung Bioepis Co, Ltd announced that the US Food and Drug Administration (FDA) has approved Ontruzant (trastuzumab─dttb), a biosimilar referencing Herceptin (trastuzumab), across all eligible indications

Medhc-fases-banner
Advertentie(s)